Technology areas: Biotechnology & Pharmaceuticals • Computing & Software • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Diabeloop has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 3 distinct examiners and 3 distinct art units, showing that the active prosecution is distributed across separate examination channels. The matching figures indicate that each identified action is associated with a different examiner and art unit.
WISE, OLIVIA M. is the busiest examiner, with 1 pending matter. The pending activity is therefore distributed rather than concentrated with this examiner. Counsel should manage the matters independently, while maintaining consistent terminology and technical positions across the biotechnology and pharmaceutical disclosures where the claim strategies overlap.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WISE, OLIVIA M. | 1 | 33.9% | +29.9% |
| PAN, YONGJIA | 1 | 65.4% | +30.8% |
| DANIEL, ANTARIUS S | 1 | 52.0% | +14.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18182263 | COMPUTERIZED SYSTEM FOR COMMUNICATING TREATMENT INFORMATION TO A USER | DANIEL, ANTARIUS S | 83d |
| 18466500 | METHOD FOR ESTIMATING AN UNANNOUNCED MEAL INGESTED | WISE, OLIVIA M. | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18182263 | COMPUTERIZED SYSTEM FOR COMMUNICATING TREATMENT INFORMATION TO A USER | DANIEL, ANTARIUS S | 83d |
| 18466500 | METHOD FOR ESTIMATING AN UNANNOUNCED MEAL INGESTED | WISE, OLIVIA M. | — |
| 18324716 | DEVICE, COMPUTERIZED METHOD, MEDICAL SYSTEM FOR DETERMINING A PREDICTED VALUE OF GLYCEMIA | PAN, YONGJIA | — |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| 2118 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18466500 | METHOD FOR ESTIMATING AN UNANNOUNCED MEAL INGESTED | WISE, OLIVIA M. | 1685 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 13, 2023 |
| 18324716 | DEVICE, COMPUTERIZED METHOD, MEDICAL SYSTEM FOR DETERMINING A PREDICTED VALUE OF GLYCEMIA | PAN, YONGJIA | 2118 | §103 | Non-Final OA | — | Pending | May 26, 2023 |
| 18182263 | COMPUTERIZED SYSTEM FOR COMMUNICATING TREATMENT INFORMATION TO A USER | DANIEL, ANTARIUS S | 3783 | §102§103§112 | Non-Final OA | 83d | Pending | Mar 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDiabeloop has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Olivia M. Wise has the most, with 1 of Diabeloop's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
